Cancer immunotherapy - PDFSEARCH.IO - Document Search Engine

Cancer immunotherapy
Results: 490

#	Item
11	PRESS RELEASE – IMMUNOCORE LIMITED Immunocore’s IMCgp100 Starts Phase I Trial for the Treatment of Uveal Melanoma (Oxford, UK, 30 MarchImmunocore, a world-leading biotechnology company developing novel T cell Add to Reading List Source URL: www.immunocore.com Language: English - Date: 2016-03-29 05:35:06 Medicine Clinical medicine Cancer Melanoma RTT Uveal melanoma Cancer treatments Immunology Oncology Uvea Immunocore Cancer immunotherapy
12	IMMUNOTHERAPIES MOVING FORWARD COMPANY Agilvax is a biotechnology company developing targeted cancer stem cell immunotherapies and vaccines for infectious diseases. The company’s Add to Reading List Source URL: www.agilvax.com Language: English - Date: 2016-07-25 22:36:40 Medicine Clinical medicine Immunology Cancer treatments Virotherapy Virus-like particle Immunotherapy Vaccine
13	British GP talking to senior man in surgery Add to Reading List Source URL: curemagazine.s3.amazonaws.com Language: English - Date: 2015-07-10 15:13:09 Medicine Clinical medicine Health Immunology Cancer treatments Oncology RTT T cells Cancer vaccine Treatment of cancer Immunotherapy Cancer
14	PRESS RELEASE – IMMUNOCORE LIMITED Immunocore’s ImmTAV shown to redirect the immune system to kill HIVinfected cells from patients treated with antiretroviral therapy - - Add to Reading List Source URL: www.immunocore.com Language: English - Date: 2016-06-10 10:46:57 Medicine Clinical medicine Immunology T cells HIV/AIDS Immune system T helper cell CD4 Management of HIV/AIDS HIV Immunocore Cancer immunotherapy
15	Safety, immune activation and anti-tumor efficacy of PEGylated recombinant human IL-10 (AM0010) Jeffrey R. Infante, MD AACR 2016 Aung Naing1, Kyriakos P. Papadopoulos2, Karen A. Autio3, Patrick A. Ott4, Manish Patel5, De Add to Reading List Source URL: www.armobio.com Language: English - Date: 2016-06-22 11:57:33 Medicine Clinical medicine Immunology Immune system T cells Cancer treatments Tumor Programmed cell death protein 1 Tumor microenvironment T helper cell Cancer immunotherapy Interleukin 10
16	12th International Workshop IMMUNOTHERAPY 2016: “Mapping the road for a long lasting immune-mediated control of cancer” Add to Reading List Source URL: www.immunotherapy.cim.co.cu Language: English - Date: 2015-12-17 09:23:28 Immunology Oncology Cancer treatments Cancer immunotherapy Immunotherapy Tumor microenvironment Adoptive cell transfer Cancer vaccine Cancer immunology Immune system Center of Molecular Immunology Cancer
17	VAXIMM Appoints Pharmaceutical Industry Veteran Dr. Jarl Ulf Jungnelius as Chief Medical Officer Basel (Switzerland) and Mannheim (Germany), May 18, 2016 – VAXIMM AG, a Swiss-German biotech company focused on developin Add to Reading List Source URL: www.biomedvc.com Language: English - Date: 2016-05-18 04:29:39 Oncology Cancer treatments Celgene Summit New Jersey Cancer immunotherapy Chemotherapy Ludwig Cancer Research Kite Pharma
18	PRESS RELEASE – IMMUNOCORE LIMITED Immunocore Presents Positive IMCgp100 Phase I Data at the 2016 ASCO Annual Meeting - Add to Reading List Source URL: www.immunocore.com Language: English - Date: 2016-06-06 05:18:35 Melanoma Immunology RTT Uveal melanoma Cancer immunotherapy Immunocore Uvea Tremelimumab DecisionDx-UM Adoptive cell transfer
19	Press Release GANYMED ANNOUNCES LICENSE OF WT1 IMMUNOTHERAPY RIGHTS BY CORIXA AND KIRIN Mainz, Germany / June 08, 2004 Ganymed Pharmaceuticals AG, Mainz, Germany, announced today that Corixa Corporation (Nasdaq: CRXA), U Add to Reading List Source URL: www.ganymed-pharmaceuticals.com Language: English - Date: 2015-02-04 05:14:56 WT1 Immunology Corixa Cancer vaccine Immunotherapy
20	ASCO Annual Meeting - Chicago, IL, May 29 –June 2, 2015; Abstract #3017 Poster #: 343 A first-in-human dose escalation study of PEGylated recombinant human IL-10 (AM0010) in advanced solid tumors. Jeffrey R. Infante1, Add to Reading List Source URL: www.armobio.com Language: English - Date: 2015-12-11 00:15:33 Immune system Immunology T cells Cancer treatments Programmed cell death protein 1 Regulatory T cell Interferon gamma Immunotherapy LAG3 Immune checkpoint CD4+ T cells and antitumor immunity Interleukin 21

UPDATE